Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-115
Last updated

Report documents

  1. Extract of dossier assessment

    Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 292 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-115_en
    Download file : Extract of dossier assessment (PDF document, 292 kB, EN, not accessible)

  2. Dossier assessment

    Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 621 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-115
    Download file : Dossier assessment (PDF document, 621 kB, DE, not accessible)

Dossier assessment

Indication:

Adults with advanced non-small cell lung cancer whose tumours have an activating human epidermal growth factor receptor 2 mutation

Result of dossier assessment:
  • Following prior treatment with platinum-based chemotherapy without immunotherapy: added benefit not proven
  • Following prior treatment with a PD-1/PD-L1 antibody in combination with platinum-based chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-based chemotherapy: added benefit not proven

Project details

Project no.
A23-115
Commission
Commission awarded on 29.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://dx.doi.org/10.60584/A23-115_en

Connected Projects

  1. Dossier assessment

    Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-07
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-08
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-80
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-81
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-54
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-128
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page